Hard for private investors to 'get on board' UK biotech bandwagon, says expert

28 March 2019

The growth of the UK’s biotech sector stands in stark and impressive contrast to many other elements of an economy that is being stagnated by financial and economic uncertainty.

A further indicator of this growth was provided this week with the UK BioIndustry Association (BIA) publishing its quarterly financing update for December 2018 to February 2019.

There was a 35% year-on-year rise in UK biotech venture capital (VC) fundraising, from £135 million ($176 million) in the first quarter of 2018 to £182 million in the first three months of this year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK